drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (adoptive T-cell therapy)
drug_description
Autologous tumor-infiltrating lymphocyte (TIL) adoptive cell therapy consisting of ex vivo–expanded, polyclonal CD8+/CD4+ T cells that recognize patient-specific tumor antigens via native TCRs and kill tumor cells through cytotoxic granules and cytokines.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous ex vivo–expanded polyclonal CD8+/CD4+ tumor-infiltrating lymphocytes that recognize patient-specific tumor antigens via native TCRs and eliminate tumor cells through perforin/granzyme-mediated cytotoxicity and cytokine secretion (e.g., IFN-γ, TNF).
drug_name
HS-IT201 Injection
nct_id_drug_ref
NCT06613152